SRZN

Surrozen, Inc. [SRZN] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SRZN Stock Summary

Top 10 Correlated ETFs

SRZN

Top 10 Correlated Stocks

SRZN

In the News

SRZN Financial details

Company Rating
-
Market Cap
21.87M
Income
-28.45M
Revenue
12.5M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
74
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-11.36
Forward P/E
-
PEG
-6.2
P/S
1.73
P/B
7.1
P/C
-
P/FCF
-0.64
Quick Ratio
6.81
Current Ratio
7.25
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-14.14
EPS next Y
-
EPS next Q
-
EPS this Y
78.49%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
9.83%
-
-
-
-
SMA20
10.65%
SMA50
-22.81%
SMA100
-25.55%
Inst Own
-
Inst Trans
-
ROA
-53%
ROE
-47%
ROC
-0.81%
Gross Margin
100%
Oper. Margin
-306%
Profit Margin
-228%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.5-16.19
52W High
-40.77%
52W Low
+136.92%
RSI
58.94
Rel Volume
0.95
Avg Volume
17.58K
Volume
16.62K
Perf Week
14.04%
Perf Month
-9.57%
Perf Quarter
-2.5%
Perf Half Y
1.9%
-
-
-
-
Beta
0.742
-
-
Volatility
0.34%, 0.89%
Prev Close
0.82%
Price
9.4767
Change
3.8%

Something similar

Top by Market Cap
V
LLY
GOOG
VFINX
MSF.DE
Top Correlated ETFs
HUG.TO
SIXH
HLTW.L
XZWG.L
WHEA.L
Top Correlated Stocks
JNJ
CYTK
AGI.TO
MNT.TO
0R0G.L
Similar Market Cap
BOXD
SRS
NUSA
0IBG.L
DYSL

Company Profile

Healthcare Biotechnology
  • Volume Average 17.58K
  • Market Capitalization 21.87M
  • Employee 74
  • CEO Mr. Craig C. Parker M.B.A.
  • Headquarters South San Francisco,CA,US
  • IPO Date 2021-01-11
  • Website https://www.surrozen.com

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.